Clinical Trial Update: Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial of trametinib for epithelioid hemangioendothelioma (locally advanced, metastatic, or unresectable) has completed with results posted on 2024-11-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelioid Hemangioendothelioma

Drugs mentioned

• MEKINIST (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma | Phase 2 | Status: COMPLETED | Results posted: 2024-11-26